HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Harmony Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$37.54−0.41 (-1.08%)
Close on Oct 19, 2026
- Market cap
- $2.21B
- P/E (TTM)
- 12.1
- Dividend yield
- –
Harmony Biosciences Holdings, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 75.4%
- Operating margin
- 24.0%
- Net margin
- 18.9%
- Return on equity, FY2025
- 20.8%
Financial strength
- Current ratio
- 3.48
- Debt to equity
- 0.15
- Debt to assets
- 11.2%
- Cash to current liabilities
- 234.9%
Valuation
- P/E ratio
- 12.1
- Price to sales
- 2.30
- Price to book
- 2.21
- Dividend yield
- –